Columbus Circle Investors’s Coherus Oncology CHRS Stock Holding History

Columbus Circle Investors’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-189,933	Closed	-$2.73M	–	291
2017 Q2	$2.73M	Sell	189,933 -33,040	-15%	-$636K	0.05%	193
2017 Q1	$4.72M	Buy	222,973 +11,792	+6%	+$290K	0.07%	195
2016 Q4	$5.95M	Sell	211,181 -104,996	-33%	-$2.94M	0.08%	179
2016 Q3	$8.47M	Sell	316,177 -57,072	-15%	-$1.56M	0.09%	178
2016 Q2	$6.3M	Buy	373,249 +154,086	+70%	+$2.89M	0.06%	198
2016 Q1	$4.65M	Sell	219,163 -57,589	-21%	-$943K	0.04%	214
2015 Q4	$6.35M	Buy	276,752 +68,666	+33%	+$1.77M	0.05%	215
2015 Q3	$4.17M	Sell	208,086 -55,451	-21%	-$1.69M	0.03%	229
2015 Q2	$7.62M	Buy	263,537 +42,712	+19%	+$1.08M	0.05%	225
2015 Q1	$6.75M	Buy	+220,825	New	+$5.71M	0.05%	229

Other funds holding CHRS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Columbus Circle Investors's CHRS Position: Q3 2017 in Review

Columbus Circle Investors sold out of Coherus Oncology (CHRS) in Q3 2017, closing a stake of 189,933 shares — an estimated $2.73M sold.

Columbus Circle Investors first reported a position in CHRS in Q1 2015 and held it in 10 quarters. The position peaked at $8.47M in Q3 2016. 93 funds tracked by Wall St. Rank hold CHRS as of Q3 2017.

Columbus Circle Investors reported no remaining Coherus Oncology position as of Q3 2017 after selling out during the quarter.
Columbus Circle Investors sold 189,933 Coherus Oncology shares in Q3 2017, an estimated $2.73M.
Columbus Circle Investors first reported a position in Coherus Oncology in Q1 2015 and held it in 10 quarters.
Columbus Circle Investors's Coherus Oncology position peaked at $8.47M in Q3 2016.
93 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2017.

Based on Columbus Circle Investors's 13F filing for Q3 2017, filed 8 Nov 2017.